佐力药业(300181) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥824,425,237.08, representing a year-on-year increase of 22.52% compared to ¥672,899,096.57 in the same period last year[4]. - The net profit attributable to shareholders was ¥181,151,432.46, up 27.20% from ¥142,415,333.77 in the previous year[4]. - The company reported a basic earnings per share of ¥0.2583, reflecting a 27.24% increase from ¥0.2030 in the same period last year[4]. - The company's net profit margin improved, with net profit attributable to the parent company increasing to ¥1,028,239,002.42, compared to ¥847,087,569.96 previously, reflecting a growth of 21.4%[16]. - The net profit for the current period is CNY 183,386,181.52, an increase of 27.3% compared to CNY 144,106,493.76 in the previous period[19]. - The total comprehensive income for the current period is CNY 305,543,707.70, up from CNY 135,283,665.64 in the previous period, representing a growth of 126.5%[19]. - Basic and diluted earnings per share for the current period are both CNY 0.2583, compared to CNY 0.2030 in the previous period, reflecting a 27.2% increase[19]. Cash Flow - The net cash flow from operating activities was -¥77,438,380.01, a significant decrease of 553.72% compared to ¥17,067,450.04 in the same period last year[4]. - The net cash outflow from operating activities was 77.44 million yuan, an increase of 94.51 million yuan year-on-year, representing a growth of 553.72%[10]. - The net cash outflow from investing activities was 129.98 million yuan, an increase of 204.14 million yuan year-on-year, representing a growth of 275.27%[10]. - The net cash inflow from financing activities was 140.08 million yuan, an increase of 162.73 million yuan year-on-year, representing a growth of 718.67%[10]. - Cash flow from operating activities shows a net outflow of CNY -77,438,380.01, a decline from a net inflow of CNY 17,067,450.04 in the previous period[21]. - Cash flow from investing activities results in a net outflow of CNY -129,980,161.09, compared to a net inflow of CNY 74,160,686.49 in the previous period[21]. - Cash flow from financing activities shows a net inflow of CNY 140,083,303.45, a significant improvement from a net outflow of CNY -22,642,770.73 in the previous period[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,569,270,953.55, an increase of 14.46% from ¥3,991,955,854.40 at the end of the previous year[4]. - Current assets totaled ¥2,436,673,465.92, a rise of 11.9% from ¥2,177,445,545.68 at the beginning of the period[16]. - Non-current assets increased to ¥2,132,597,487.63, up 17.5% from ¥1,814,510,308.72[16]. - Current liabilities rose to ¥1,211,726,378.45, an increase of 14.7% from ¥1,056,049,174.34[16]. - Non-current liabilities totaled ¥176,247,420.58, up 51.5% from ¥116,465,923.94[16]. - The company's total liabilities increased, with short-term borrowings rising by 22.23% to ¥46,119.37 million[8]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,228[11]. - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, totaling 129,890,463 shares, with 64,500,000 shares pledged[11]. - The company plans to grant 5.855 million restricted stocks at a price of 8.07 yuan per share as part of its 2024 incentive plan[13]. - The company will complete the transfer of 5.975 million shares to the 2024 employee stock ownership plan at a price of 8.07 yuan per share[13]. - The repurchase account holds 8,920,074 shares, accounting for 1.27% of the total share capital[12]. - The company has no preferred shareholders or significant changes in the top 10 shareholders due to margin trading[13]. - The company has not disclosed any related party relationships among the top 10 shareholders[12]. Operating Performance - The company's gross profit margin decreased due to a higher growth rate in operating costs (43.77%) compared to revenue growth (22.52%)[9]. - The sales revenue of the company's traditional Chinese medicine products increased significantly, with a 50.64% growth in Chinese medicine formula granules and a 26.39% increase in Chinese medicine pieces[9]. - Total operating revenue for the current period reached ¥824,425,237.08, an increase of 22.5% compared to ¥672,899,096.57 in the previous period[18]. - Total operating costs amounted to ¥623,213,469.79, up 20.1% from ¥519,085,030.36 in the prior period[18]. Other Comprehensive Income - The company’s other comprehensive income increased by 119.42% to ¥20,762.59 million, primarily due to the rise in market value of its investment in CARsgen Therapeutics Holdings Limited[8]. - The other comprehensive income attributable to the parent company is CNY 113,000,598.02, compared to a loss of CNY -8,161,468.92 in the previous period[19].